ABSTRACT
Development of nanoparticulates arose in response to broad medical needs, common to a number of therapeutic areas and targets. Earlier work on liposomes and emulsions had established iconic examples of enhancements that drug delivery could confer on established agents such as doxorubicin and amphotericin. These involved improvements in pharmacokinetics as well as in targeting to certain organs, cell types, or organelles. Although its in vivo disposition was altered, the molecular structure of the drug was not changed, thus facilitating overall development. For broader applicability,
PART III: DRUG DELIVERY APPLICATIONS OF NANOPARTICLES
nanosuspensions offer additional features, compelling their current popularity. As contrasted with microparticulates, nanoparticulates are sufficiently small to avoid embolism associated with intravenous (i.v.) delivery, and can also be used for the less invasive parenteral routes.
